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Recent impressive results incorporating anti-HER2 therapy as part of adjuvant treatment for patients with resected breast cancer are based on optimal patient selection based on clinical characteristics and tumor biomarkers of response. 
[Perezetal.,2006;Paiketal.,2005]. Quality control using either immunohistochemistry 
or gene analysis for HER2 is critical for patient selection. 
Update of results of major adjuvant trastuzumab studies
The ongoing NCCTG N9831 Intergroup and NSABP B-31 adjuvant trials evaluate 
the role of adding trastuzumab (H) to the AC-T regimen in patients with resected 
node-positive or high-risk node negative breast cancer (B-31 enrolled node-negative 
patients only) that over expresses or amplifies HER2 [Romond,Perezetal.,NEJM2005]. 
HERA (HERceptin Adjuvant) is evaluating adjuvant trastuzumab after completion of 
chemotherapy (with or without radiation) [PiccartMetal.,2005;Smithetal.,2006]. The 
BCIRG 006 adjuvant trial is evaluating the benefit of 2 trastuzumab-based regimens in 
HER2 amplified breast cancer and includes 2 anthracycline-containing arms [Slamonet
al.,2005]. Recently reported data from these trials demonstrate impressive DFS (in all 
of the trials) and overall survival (OS) (in the joint analysis of N9831 and B-31) benefits 
with adjuvant chemotherapy-trastuzumab vs chemotherapy only.
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N9831 enrolled patients into one of three arms: Arm A was doxorubicin plus cyclo-
phosphamide (AC) followed by paclitaxel (T), Arm B was AC followed by T, followed by 
trastuzumab (H) (sequential treatment), and Arm C was AC followed by TH (concur-
rent treatment) [Perezetal.,2005]. NSABP B-31 enrolled patients into one of two arms: 
AC followed by T or AC followed by TH. A joint analysis of the AC followed by T vs the 
AC followed by TH arm at a median follow-up of 2 years is available for these 2 trials 
[Romond,Perez et al.,NEJM2005]. In the HERA trial, following the completion of 
chemotherapy, patients were randomized to H for 1 year, H for 2 years, or observation. 
Data are available at a median follow-up of 2 years for the HERA trial [Smithetal.,
2006]. The BCIRG trial includes 2 anthracycline arms, 1 with concurrent trastuzumab 
and taxane, and a trastuzumab-nonanthracycline regimen. Median follow up at the time 
of the most recent report (december 2005) was 23 months [Slamonetal.,2005]. 
In the joint analysis of N9831 and NSABP B-31, DFS was 85% at 4 years for patients 
treated with AC followed by TH, compared with 67% in the control arm of AC followed 
by T (HR: 0,48, IC95: 0,39 to 0,59; p < 0,0001) [Romond, Perez et al.,NEJM2005]. 
Findings in the HERA trial were consistent with those of the joint analysis. HERA repor-
ted a 2-year DFS of 86% after 1 year of trastuzumab vs 77% after 1 year of observation 
(HR: 0,54, IC95: 0,43 to 0,67; p < 0,0001) [Piccart-Gebhartetal.,2005]. In both the joint 
analysis and the HERA trial, all evaluated subsets derived a strong relative benefit from 
trastuzumab. There was a statistically significant improvement in distant disease-free 
survival (DDFS) as well, with a hazard ratio (HR) for DDFS of 0,47 (IC95: 0,37 to 0,61 p 
< 0,0001) in the joint analysis and 0,49 (IC95: 0,38 to 0,63; p < 0,0001) for the HERA trial. 
The joint analysis reported a 33% decrease in mortality with trastuzumab (HR: 0,67, 
IC95: 0,48 to 0,98; p = 0,015). Moreover, the HERA trial has now demonstrated an OS 
at a median follow up of 2 years (HR: 0,76, p = 0,26) [Romond,Perezetal.,NEJM2005;
Smithetal.,2006]. When the results of N9831 are looked at individually, they suggest 
that concurrent therapy may be superior to sequential therapy, and not associated with 
more cardiotoxicity [Perezetal.,2006]. Moreover, cardiac safety of concurrent radiation 
with trastuzumab were reported from N9831 [Halyardetal.,2006].
Optimal duration of adjuvant trastuzumab
The ideal duration of trastuzumab administration is under investigation, although 
most of the beneficial data reported so far are based on 1 year therapy. Recent provoca-
tive data in a very small number of patients suggest that even short-term trastuzumab 
may be effective in preventing recurrence. 
The results of the recently reported FinHER adjuvant therapy trial [Joensuuetal.,
2006] demonstrate that trastuzumab plus a taxane or vinorelbine for 9 weeks followed 
by three 3-weekly cycles of FEC is well tolerated and effective in preventing recurrence 
of ErbB2 amplified breast cancer. However, the IC95 for the hazard ratio for recurrence-
free survival is quite wide (0,21-0,83), and based on only 27 events in the two non-
Thérapie adjuvante anti-HER2 : nouvelles données
28es journées de la SFSPM, Lille, novembre 20064
trastuzumab arms and 12 events in the two trastuzumab arms. The question of shorter 
duration of trastuzumab of less than one year is now being addressed by the French 
Breast Group, in a trial initiated in 2006. These investigators plan to enroll 8000 women 
to receive either 6 months or 12 months of trastuzumab after completing chemotherapy 
and radiation as indicated.
Additional anti-HER2 strategies beyond trastuzumab
Despite the impressive results of the recently released trastuzumab adjuvant therapy 
trials, 15% of patients with HER2 overexpressing or amplified breast cancer developed 
tumor relapse at 3 years, and there is some concern related to site-specific metasta-
ses–including brain. 
Several pan-HER or dual HER inhibitors are at different stages of development, but 
lapatinib is the most advanced. Lapatinib is a reversible tyrosine kinase inhibitor (TKI) 
that potently inhibits both ErbB1 and ErbB2 tyrosine kinase activity. In breast cancer 
cell lines (with 100-fold selectively for cancer cells vs a normal human cell line) treated 
with lapatinib, growth arrest and cell death were observed. Lapatinib also selectively 
inhibits tumor xenograft growth in a dose-dependent manner [Rusnaketal.,2001]. In a 
pilot study conducted in patients with metastatic tumors overexpressing ErbB2 and/or 
expressing ErbB1, biopsy specimens from responders treated with lapatinib exhibit 
increased apoptosis, while specimens obtained from non responders did not [Spector,
Xiaetal.,2005]. 
This agent has undergone preclinical, phase I, pharmacokinetic, as well as phase II 
and III evaluation in the setting of HER2 positive metastatic beast cancer, with impres-
sive data. Pharmacokinetics data show incomplete and highly variable oral absorption 
that increases with food, metabolism primarily by CYP 3A4/5, and a half-life of approxi-
mately 24 hours.
The single agent activity of lapatinib has been demonstrated in phase II studies of 
patients previously treated with trastuzumab, but also in patients who had not received 
trastuzumab.
Although both trastuzumab and lapatinib inhibit the same receptor, ErbB2, the 
combination is potentially attractive because each agent targets a different part of the 
receptor, with trastuzumab targeting the extracellular domain and lapatinib the intra-
cellular domain. In addition, they appear to have different mechanisms of action, with 
trastuzumab activity at least in part due to increased internalization and degradation 
of ErbB2 and lapatinib inhibiting the ErbB2 tyrosine kinase. This differentiation may 
lead to sustained inhibition of activation of the receptors, and possibly to enhanced 
inhibitory signals 
Currently, there are several phase III studies ongoing to evaluate lapatinib in patients 
with metastatic breast cancer. The EGF100151 randomized, open-label trial is compa-
ring capecitabine with and without lapatinib in patients with HER2 overexpressing 
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disease who have been previously exposed to anthracycline, taxane, and trastuzumab. 
The study yielded a highly statistically significant improvement in time to progression 
for the patients assigned to capecitabine plus lapatinib compared to those who received 
capecitabine alone, in the range of 5 months [Geyeretal.,ASCO2006].
An analysis of cardiac safety of lapatinib was also presented at ASCO 2006 [Perezet
al.,2006]. The data were based on more than 3000 patients enrolled to lapatinib trials, 
approximately half of them with breast cancer, who had received anthracyclines and/or 
trastuzumab. The other half of the patients had tumor types different than breast and 
had not received trastuzumab. Evaluation of cardiac ejection fraction was made every 
2 months, added to clinical follow up. The results demonstrate only a 1,3% of decreases 
of LVEF and a rate of symptomatic cardiac events of only 0,1%. These data demonstrate 
that this agent appears to be quite safe from the cardiac standpoint, although additional 
follow up is ongoing.
Data from ongoing trials, added to our improved understanding of targeted therapies 
allows us an opportunity to develop new translational trials to improve outcomes in 
patients with resected HER2+ breast cancer. Patient follow up from all of the reported 
trastuzumab adjuvant trials will continue, concentrating on long term efficacy, safety 
especially cardiac), correlative studies of clinical characteristics with outcome, as well as 
translational studies of molecular tumor markers with response. Some of these markers 
include c-myc, PTEN, topoisomerase II alpha, cyclin D1, IGFR-1, amongst others. 
Trials are being developed on a worldwide basis, incorporating adjuvant lapatinib. 
Some of the issues to be explored in these studies include: Efficacy of lapatinib alone, 
lapatinib in combination with trastuzumab, or sequential use of lapatinib followed by 
trastuzumab (in the setting of appropriate chemotherapy – with the patients starting 
trastuzumab preferably concurrent with taxane in view of preclinical data, results in 
the metastatic setting, as well as data from PerezetalaspartofN9831. In addition, 
“recurrence samples” will be collected, when available, in order to better understand the 
biology of disease that recurs during or soon after HER2-directed therapy.  This collec-
tion will also give us insight as to differences between resistance to trastuzumab, lapati-
nib, the combination of trastuzumab and lapatinib and may suggest novel therapeutic 
strategies. Safety and quality of life issues will also be important part of new studies.
Références bibliographiques
•BlackwellKL,BursteinH,PegramMetal.Determiningrelevantbiomarkersfromtissueandserum
thatmaypredictresponsetosingle-agentlapatinibintrastuzumabrefractorymetastaticbreastcancer.
ProcAmSocClinOncol2005;23(16S):193.
•BlackwellKL,KaplanEH,FrancoSXetal.AphaseII,open-label,multicenterstudyofGW572016
in patients with trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol
2004;22(14S):196.
•EarpHS,DawsonTL,LiX,YuH.HeterodimerizationandfunctionalinteractionbetweenEGF
receptorfamilymembers:anewsignalingparadigmwithimplicationsforbreastcancerresearch.Breast
CancerResTreat1995;35:115-132.
Thérapie adjuvante anti-HER2 : nouvelles données
28es journées de la SFSPM, Lille, novembre 20066
•GeyerCE,BryantJL,RomondEHetal.UpdateofcardiacdysfunctiononNSABPB-31,arandomized
trialofsequentialdoxorubicin/cyclophosphamide(AC)→paclitaxel(T)vs.AC→Twithtrastuzumab
(H)(Abst581).ProcAmSocClinOncol2006;24(18S):23.
•GomezHL,ChavezMA,DovalDCetal.AphaseII,randomizedtrialusingthesmallmolecule
tyrosinekinaseinhibitorlapatinibasafirst-linetreatmentinpatientswithFISH-positiveadvancedor
metastaticbreastcancer.ProcAmSocClinOncol2005;23(16S):203.
•HalyardM,PisanskyTM,SolinLJetal.Adjuvantradiotherapy(RT)andtrastuzumabinstageI-IIA
breastcancer:toxicitydatafromNorthCentralCancerTreatmentGroupPhaseIIITrialN9831.Proc
AmSocClinOncol2006;24(18S):8.
•JoensuuH,Kellokumpu-LehtinenP-L,BonoPetal.Trastuzumabincombinationwithdocetaxel
orvinorelbineasadjuvanttreatmentofbreastcancer:theFinHerTrialBreastCancerResTreat
2005;94(Suppl.1):S5.
•JonesSF,BurrisHA,YardleyDAetal.Lapatinib(anoraldualkinaseinhibitor)plusweeklyorevery
3weekpaclitaxel.BreastCancerResTreat2004;88(Suppl.1):S64.
•KonencyGE,PegramMD,VenkatesanNetal.Activityofthedualkinaseinhibitorlapatinib
(GW572016)againstHER-2-overexpressingandtrastuzumab-treatedbreastcancercells.CancerRes
2006;66(3):1630-9.
•LapatinibInvestigator’sBrochure.GlaxoSmithKline,2006.
•MinamiH,NakagawaK,KawadaKetal.AphaseIstudyofGW572016inpatientswithsolidtumors
ProcAmSocClinOncol2004;23:207.
•PaikS,BryantJ,Tan-ChiuEetal.Real-worldperformanceofHER2testing–NationalSurgical
AdjuvantBreastandBowelProjectExperience.JNatlCancerIns2002;94(11):852-4.
•PerezEA,SumanVJ,DavidsonNetal.OnbehalfofNCCTG,ECOG,SWOG,CALGB.Advancesin
monoclonalantibodytherapyforbreastcancer:furtheranalysisofNCCTGN9831.Paperpresentedat:
AmericanSocietyofClinicalOncologyAnnualMeeting;May16,2005;Orlando,Florida.
•PerezEA,SumanVJ,DavidsonNEetal.HER2testingbylocal,central,andreferencelaboratoriesin
specimensfromtheNorthCentralCancerTreatmentGroupN9831IntergroupAdjuvantTrial.JClin
Oncol2006;24(19):3032-8.
•PerezEA,ByrneJA,HammondIWetal.Resultsofananalysisofcardiacfunctionin2812patients
withlapatinib.ProcAmSocClinOncol2006;24(18S):23.
•Piccart-GebhartMJ,ProcterM,Leyland-JonesBetal.Trastuzumabafteradjuvantchemotherapy
inHER2-positivebreastcancer.NEnglJMed2005;353:1659-72.
•RomondEH,PerezEA,BryantJetal.TrastuzumabplusadjuvantchemotherapyforoperableHER2-
positivebreastcancer.NEnglJMed2005;353:1673-84.
•RusnakDW,LackeyK,AffleckKetal.Theeffectsofthenovel,reversibleepidermalgrowthfactor
receptor/ERbB-2tyrosinekinaseinhibitor,GW2016,onthegrowthofhumannormalandtumor-
derivedcelllinesinvitroandinvivo.MolecCancerTherap2001;1:85-94.
•SlamonD,EiermannW,RobertNetal.PhaseIIIrandomizedtrialcomparingdoxorubicinand
cyclophosphamidefollowedbydocetaxel(AT-T)withdoxorubicinandcyclophosphamidefollowedby
docetaxelandtrastuzumab(AC-TH)withdocetaxel,carboplatinandtrastuzumab(TCH)inHER2
positiveearlybreastcancerpatients:BCIRG006study.BreastCancerResTreat2005;94:S62.
•SmithI.TrastuzumabfollowingadjuvantchemotherapyinHER2-positiveearlybreastcancer(HERA
Trial):Disease-freeandoverallsurvivalafter2yearmedianfollow-up.Presentedat:AmericanSociety
ofClinicalOncologyAnnualMeetingScientificSpecialSession;June3,2006;Atlanta,Georgia.
E. Perez
28es journées de la SFSPM, Lille, novembre 2006 
•SpectorN,LiuL,GerardCetal.Combininglapatinib(GW572016)withanti-erbB2antibodies
elicitssynergisticapoptoticeffectsinerbB2overexpressingbreastcancercells.ProcAmSocClinOncol
2005;23(16S):18.
•SpectorNL,XiaW,BurrisHetal.Studyofthebiologiceffectsoflapatinib,areversibleinhibitorof
ErbB1andErbB2tyrosinekinases,ontumorgrowthandsurvivalpathwaysinpatientswithadvanced
malignancies.JClinOncol2005;23:2503-12.
•StornioloAM,BurrisHA,OvermoyerBetal.AphaseI,open-labelstudyofthesafety,tolerability,
andpharmacokineticsoflapatinib(GW572016)incombinationwithtrastuzumab.BreastCancer
ResTreat2005;94:S64.
•VersolaM,BurrisHA,JonesSetal.ClinicalactivityofGW572016inEGF10003inpatientswith
solidtumors.ProcAmSocClinOncol2004;22(14S):213.
•WewersME,LoweNK.Acriticalreviewofvisualanaloguescalesinthemeasurementofclinical
phenomena.ResNursingHealth1990;13:227-36.
•WoodburnJR.Theepidermalgrowthfactorreceptoranditsinhibitionincancertherapy.Pharmacol
Therap1999;82:241-50.
•XiaW,GerardCM,LiuLetal.Combininglapatinib(GW572016),asmallmoleculeinhibitorof
ErBB1andErbB2tyrosinekinases,withtherapeuticanti-ErbB2antibodiesenhancesapoptosisof
ErbB2-overexpressingbreastcancercells.Oncogene2005;24:6213-21.
•ZhouH,KimYS,PeletierAetal.EffectsoftheEGFR/HER2kinaseinhibitorGW572016onEGFR-
andHER2-overexpressingbreastcancercelllineproliferation,radiosensitization,andresistance.IntJ
RadiatOncolBiolPhys2004;58:344-52.
Thérapie adjuvante anti-HER2 : nouvelles données
